Agata Czarnywojtek

Agata Czarnywojtek

Auto-generated profile, based on publicly available information

Agata Czarnywojtek

Department of Endocrinology, Metabolism and Internal Medicine, Poznań University of Medical Sciences, 60-355 Poznań, Poland

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Archives of Medical Science
Verified
Journal Article
Open access
PGPaweł Gut
Paweł Gut
ACAgata Czarnywojtek
Agata Czarnywojtek
JFJakub Fischbach
Jakub Fischbach
MBMaciej Bączyk
Maciej Bączyk
KZKatarzyna Ziemnicka
Katarzyna Ziemnicka
MRMarek Ruchała
Marek Ruchała
Chromogranin A, despite a number of limitations, is still the most valuable marker of neuroendocrine tumors (NETs). Granins belong to the family of acidic proteins that constitute a major component of secretory granules of various endocrine and neuroendocrine cells, which are components of both...

14 February 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KWKosma Wolinski
Kosma Wolinski
ACAgata Czarnywojtek
Agata Czarnywojtek
MRMarek Ruchala
Marek Ruchala
Acromegaly is a quite rare chronic disease caused by the increased secretion of growth hormone (GH) and subsequently insulin - like growth factor 1. Although cardiovascular diseases remains the most common cause of mortality among acromegalic patients, increased prevalence of malignant and benign neoplasms remains a matter of debate. The aim of this study is to evaluate the risk of thyroid nodular disease (TND) and thyroid cancer in patients with acromegaly. PubMed, Cochrane Library, Scopus, Cinahl, Academic Search Complete, Web of Knowledge, PubMed Central, PubMed Central Canada and Clinical Key databases were searched to identify studies containing. Random–effects model was used to calculate pooled odds ratios and risk ratios of TND in acromegaly. Studies which not included control groups were systematically reviewed. TND was more frequent in acromegaly than in control groups (OR = 6.9, RR = 2.1). The pooled prevalence of TND was 59.2%. Also thyroid cancer (TC) proved to be more common in acromegalic patients (OR = 7.5, RR = 7.2), prevalence was 4.3%. The pooled rate of malignancy (calculated per patient) was equal to 8.7%. This study confirms that both TND and TC occur significantly more often in acromegalic patients than in general population. These results indicate that periodic thyroid ultrasound examination and careful evaluation of eventual lesions should be an important part of follow-up of patients with acromegaly.

4 February 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
IKIwona Krela-Kaźmierczak
Iwona Krela-Kaźmierczak
ACAgata Czarnywojtek
Agata Czarnywojtek
KSKinga Skoracka
Kinga Skoracka
ARAnna Maria Rychter
Anna Maria Rychter
ARAlicja Ewa Ratajczak-Pawłowska
Alicja Ewa Ratajczak-Pawłowska
ADAgnieszka Dobrowolska
Agnieszka Dobrowolska
Iodine deficiency is a global issue and affects around 2 billion people worldwide, with pregnant women as a high-risk group. Iodine-deficiency prevention began in the 20th century and started with global salt iodination programmes, which aimed to improve the iodine intake status globally. Although it resulted in the effective eradication of the endemic goitre, it seems that salt iodination did not resolve all the issues. Currently, it is recommended to limit the consumption of salt, which is the main source of iodine, as a preventive measure of non-communicable diseases, such as hypertension or cancer the prevalence of which is increasing. In spite of the fact that there are other sources of iodine, such as fish, seafood, dairy products, water, and vegetables, the high consumption of processed food with a high content of unionised salt, alternative diets or limited salt intake can still lead to iodine deficiency. Thus, iodine deficiency remains a relevant issue, with new, preventive solutions necessary. However, it appears that there is no diet which would fully cover the iodine requirements, and iodine food supplementation is still required.

1 March 2012 in European Journal of Endocrinology
Verified
Journal Article
Closed access
MRMarek Ruchala
Marek Ruchala
ESEwelina Szczepanek-Parulska
Ewelina Szczepanek-Parulska
AZAriadna Zybek
Ariadna Zybek
JMJerzy Moczko
Jerzy Moczko
ACAgata Czarnywojtek
Agata Czarnywojtek
JSJerzy Sowinski
Jerzy Sowinski
Objective: Reports on sonoelastography, which provide an objective estimation of tissue elasticity, are scarce in terms of thyroiditis. The aim of this study was to prospectively assess the applicability of sonoelastography in different types of thyroiditis.Design: The study assessed and compared the thyroid tissue stiffness in patients with acute thyroiditis (AT), subacute thyroiditis (SAT), and chronic autoimmune thyroiditis (CAT) with healthy control subjects (CS), followed up for 10 weeks.Methods: The study group consisted of two patients with AT, 18 patients with SAT, 18 patients with CAT, and 40 CS matched for age and gender. Sonoelastography was performed at baseline, at a 4-week follow-up during treatment, and at 10 weeks following diagnosis and treatment initiation.Results: Thyroid tissue stiffness was higher in SAT at baseline (214.26±32.5 kPa) in comparison with values recorded at a 4-week follow-up (45.92±17.4 kPa) and at 10 weeks following diagnosis and treatment initiation (21.65±5.3 kPa, P<0.0001). Baseline thyroid stiffness in SAT was higher than that found in CAT (36.15±18.7 kPa, P<0.0001) and CS (16.18±5.4 kPa, P<0.0001). In the remission of SAT, thyroid stiffness was lower than that found in CAT (P=0.006), while it was higher than that in CS (P=0.0008). No difference was observed between thyroid stiffness in SAT at 4-week follow-up and in CAT. Patients with CAT presented higher thyroid stiffness than CS (P<0.0001), which was not influenced by l-thyroxine treatment. Thyroid stiffness in patients with AT was 216.6 and 241.9 kPa at baseline; after treatment, it decreased to 17.93 and 85.348 kPa respectively.Conclusions: Sonoelastography may assist in the diagnosis and treatment monitoring of AT, SAT and CAT, as well as in the differentiation of the various types of thyroiditis.

1 January 2010 in European Journal of Endocrinology
Verified
Journal Article
Closed access
MRMarek Ruchala
Marek Ruchala
ESEwelina Szczepanek
Ewelina Szczepanek
WSWitold Szaflarski
Witold Szaflarski
JMJerzy Moczko
Jerzy Moczko
ACAgata Czarnywojtek
Agata Czarnywojtek
JSJerzy Sowinski
Jerzy Sowinski
Objective: Thyroid hemiagenesis (THA) is an anomaly resulting from the developmental failure of one thyroid lobe. Etiopathogenesis, clinical significance, and management of patients in whom THA is diagnosed are still a matter of debate. The aim of the study is to provide the first systematic analysis of a large cohort of subjects with THA.Design: Forty patients with THA are described in comparison to a control group of 80 subjects with fully developed thyroid gland.Methods: Serum concentrations of thyrotropin (TSH), free thyroxine (FT4), free triiodothyronine (FT3), and thyroid autoantibodies were measured. In 37 patients, thyroid ultrasonography and Tc-99m thyroid scintiscan were performed, followed by fine-needle aspiration biopsy if indicated. The remaining archival three cases were diagnosed with the use of I-131 scintiscan under basal conditions and after TSH stimulation.Results: Patients with THA, while usually clinically euthyroid, presented with significantly higher levels of TSH and FT3 as well as with higher FT3/FT4 concentration in comparison to the control group. Furthermore, a higher incidence of associated functional, morphological, and autoimmune thyroid disorders in patients with THA was observed when compared to subjects with bilobate thyroid (P<0.05).Conclusions: Our results revealed that individuals with THA are more likely to develop thyroid pathology. The observed high incidence of associated pathologies is presumably due to long-lasting TSH overstimulation. Therefore, THA diagnosis should be followed by systematic observation and adequate levothyroxine treatment in patients with elevated TSH level.

20 December 2018 in Endokrynologia Polska
Verified
Journal Article
Open access
PDF file
MBMagdalena Borowska
Magdalena Borowska
ACAgata Czarnywojtek
Agata Czarnywojtek
NSNadia Sawicka-Gutaj
Nadia Sawicka-Gutaj
KWKosma Wolinski
Kosma Wolinski
MPMaria Teresa Płazińska
Maria Teresa Płazińska
MRMarek Ruchała
Marek Ruchała
Cannabinoids are the derivatives of the cannabis plant, the most potent bioactive component of which is tetrahydrocannabinol (THC). The most commonly used drugs containing cannabinoids are marijuana, hashish, and hashish oil. These compounds exert their effects via interaction with the cannabinoid receptors CB1 and CB2. Type 1 receptors (CB1) are localised mostly in the central nervous system and in the adipose tissue and many visceral organs, including most endocrine organs. Type 2 cannabinoid receptors (CB2) are positioned in the peripheral nervous system (peripheral nerve endings) and on the surface of the immune system cells. Recently, more and more attention has been paid to the role that endogenous ligands play for these receptors, as well as to the role of the receptors themselves. So far, endogenous cannabinoids have been confirmed to participate in the regulation of food intake and energy homeostasis of the body, and have a significant impact on the endocrine system, including the activity of the pituitary gland, adrenal cortex, thyroid gland, pancreas, and gonads. Interrelations between the endocannabinoid system and the activity of the endocrine system may be a therapeutic target for a number of drugs that have been proved effective in the treatment of infertility, obesity, diabetes, and even prevention of diseases associated with the cardiovascular system. Cannabinoids are the derivatives of the cannabis plant, the most potent bioactive component of which is tetrahydrocannabinol (THC). The most commonly used drugs containing cannabinoids are marijuana, hashish, and hashish oil. These compounds exert their effects via interaction with the cannabinoid receptors CB1 and CB2. Type 1 receptors (CB1) are localised mostly in the central nervous system and in the adipose tissue and many visceral organs, including most endocrine organs. Type 2 cannabinoid receptors (CB2) are positioned in the peripheral nervous system (peripheral nerve endings) and on the surface of the immune system cells. Recently, more and more attention has been paid to the role that endogenous ligands play for these receptors, as well as to the role of the receptors themselves. So far, endogenous cannabinoids have been confirmed to participate in the regulation of food intake and energy homeostasis of the body, and have a significant impact on the endocrine system, including the activity of the pituitary gland, adrenal cortex, thyroid gland, pancreas, and gonads. Interrelations between the endocannabinoid system and the activity of the endocrine system may be a therapeutic target for a number of drugs that have been proved effective in the treatment of infertility, obesity, diabetes, and even prevention of diseases associated with the cardiovascular system.